Generics BulletinFresenius Kabi will look to launch its denosumab biosimilars to Prolia and Xgeva in the US in mid-2025, after the German firm received US Food and Drug Administration approval for the biosimilars – th
Generics BulletinPierluigi Antonelli was less than three months into his role as a member of the Management Board of Fresenius, responsible for the group’s operating company Fresenius Kabi, when he recognised an eye
Generics Bulletin“We are a simpler, stronger, and more focused company. 2024 looks to be a great year with excellent financial progression,” Fresenius ’ CEO Michael Sen did not hide his enthusiasm about the future du
Generics BulletinThe Fresenius group has ramped up its cost savings target through to 2025 after overdelivering by more than 40% its 2023 goal, driven by a much leaner operation at its core Fresenius Kabi pharma, nu